

HEALTHCARE: ITALY ON THE MOVE 2020

START-UP PITCHING SESSION

JANUARY 13th, 2020
Consulate General of Italy - San Francisco



INDEX

	<i>Pag.</i>
ALTHEIA SCIENCE S.R.L.	6
BIOUNIVERSA S.R.L.	7
CELLPLY S.R.L.	8
EXOSOMICS S.P.A.	9
GENENTA SCIENCE S.P.A.	10
GENOMEUP S.R.L.	11
MULTIPLY LABS	12
PETRONE GROUP S.R.L.	13
ROTTAPHARM BIOTECH S.R.L.	14
TETHIS S.P.A.	15
WISE S.R.L.	16



START-UP





ALTHEIA SCIENCE S.R.L.

AREA OF ACTIVITY

Medical research

FOUNDATION

01/12/17

COMPANY SIZE

Turnover

Less than 75.000 Euro

Employees

From 3 to 9 employees

INFO

HEADQUARTER

Via Enrico Besana, 7
Milan (MI)
Italy
www.altheiascience.com

KEY CONTACT

Paolo Rizzardi

Chairman&CEO
paolo.rizzardi@altheiascience.com
+39 335 1935042

Gabriele Campi

Project Manager
gabriele.campi@altheiascience.com
+39 320 0673899

Asset type

Gene Therapy

Asset Development Phase

Preclinical

Meeting's Goal

Completed Round A in 2018, banking €17M from private investors. The Company intends to open discussions with new investors for a Round B financing.

Clinical indication / Target market

Transformative therapies for type 1 diabetes (T1D) and multiple sclerosis (MS), characterized by autoimmune destruction of insulin-producing β cells and myelin, respectively, leading to severe clinical sequelae, life-threatening conditions and death.

Asset Description

The modulation of PD-L1 expression at the molecular and protein level is key to devise advanced treatments in autoimmune diseases and this can be achieved by lentiviral vector-based engineering of patients' hematopoietic stem and progenitor cells (HPSCs). In particular, Altheia Science develops a gene therapy-based approach in type 1 diabetes (T1D) and multiple sclerosis (MS) that aims at reverting the root cause of the disease, by ex vivo lentiviral vector-transducing autologous HSPCs to reconstitute PD-L1 expression, achieving durable clinical benefits.

NOTES



AREA OF ACTIVITY

Biotech

FOUNDATION

26/06/09

COMPANY SIZE

Turnover

From 250.000 to 750.000 Euro

Employees

Less than 3 employees

INFO

HEADQUARTER

Via Antonio Gramsci, 85
Montoro (AV)
Italy
www.biouniversa.com

KEY CONTACT

Giovanni Rizzo

CEO
giovanni@biouniversa.com
+39 335 1089315

Maria Pilar Caballero

Executive Assistant
pilar@biouniversa.com

Asset type

Antibody

Asset Development Phase

Planning phase 1 in a year time.

Meeting's Goal

Out-Licensing/ partnership.

Clinical indication / Target market

Pancreatic Cancer.

Asset Description

It has been shown that pancreatic tumor cells produce and secrete a protein, Bag3, that inhibits the immune system to attack tumor cells. Biouniversa developed, and preclinically validated, a specific Bag3 antibody that inhibits the activity of Bag3 which modulates the immune system to attack tumor cells thus reducing its growth. Biouniversa antibody is now being developed for the clinical phase by IntrepidaBio, a San-Diego based company.

NOTES

AREA OF ACTIVITY

Laboratory equipment, reagents, software

FOUNDATION

18/12/13

COMPANY SIZE

Turnover

Less than 75.000 Euro

Employees

From 10 to 19 employees

INFO

HEADQUARTER

Via Fondazza, 53
Bologna (BO)
Italy
www.cellply.com

KEY CONTACT

Massimo Bocchi

CEO
massimo.bocchi@cellply.com
+39 051 0397670

Asset type

In-V itro Diagnostic platform

Asset Development Phase

A BETA version of the platform has been developed and installed in 2 partner hospitals. Platform industrialization is currently ongoing in collaboration with a multinational company. A clinical proof completed on leukemia patients reported a close to 90% correlation between Cellply test and clinical outcome. Next step is the start of commercial activities.

Meeting's Goal

Seeking investors for an €6m Series Around / partners interested in activating CDx programs and co-development activities.

Clinical indication / Target market

Precision cancer tests covered by the Cellply platform target an addressable population of about 1.2 million patients in EU and US with hematologic tumors and selected advanced tumors, e.g. lung, ovarian, colorectal cancer, including patients treated with immunooncology drugs and targeted drugs.

Asset Description

Cellply developed the first system that, starting from a blood sample or biopsy, entirely automates the ex-vivo analysis of patients' tumor cell response to cancer treatments in 24 hours or less. The platform allows to run functional tests in any clinical and research lab to evaluate the efficacy of a wide range of treatments, including complex immuno-oncology drugs requiring a characterization of the patient's tumor and immune system. The system supports the development of a new concept of precision medicine based on phenotypic data, advancing genomic-based precision medicine.

NOTES

AREA OF ACTIVITY

Liquid Biopsy, Diagnostic IVD

FOUNDATION

26/06/11

COMPANY SIZE**Turnover**

From 250.000 to 750.000 Euro

Employees

From 20 to 49 employees

INFO**HEADQUARTER**

Strada del Petriccio e Belriguardo, 35
Siena (SI)
Italy
www.exosomics.eu

KEY CONTACT**Antonio Chiesi**

CEO
achiesi@exosomics.eu
+39 349 2921369

Behzad Mahdavi

President of the Board
behzad.mahdavi@lonza.com

Asset type

Medical Devices, Pre-analytical solutions, Diagnostics kits (IVD)

Asset Development Phase

Pre-analytical solutions for liquid biopsy: Commercial-stage. Medical devices: prototype stage. Pan-Cancer screening assays: analytical, validation stage

Meeting's Goal

Fundraising Series Around.

Clinical indication / Target market

Re-analytical solutions for liquid biopsy in cancer precision medicine. Analytical solutions producers Pan-Cancer screening assay. Diagnostic industry.

Asset Description

SeleCTEV: affinity isolation of tumor exosomes + cfDNA and DNA extraction kit. SoRT EV: affinity isolation of tumor exosomes and RNA extraction kit. ExoRef: lyophilized exosome reference standard bearing several cancer mutations. LB-Easy: device for plasma collection liquid biopsy ready. Cancer rEveal: pan-cancer screening assay.

NOTES

AREA OF ACTIVITY

Biotech

FOUNDATION

24/07/14

COMPANY SIZE

Turnover

Less than 75.000 Euro

Employees

From 3 to 9 employees

INFO

HEADQUARTER

Via Olgettina, 58
Milan (MI)
Italy
www.genenta.com

KEY CONTACT

Pierluigi Paracchi

Chairman & CEO
pierluigi.paracchi@genenta.com
+39 335 7351868

Carlo Russo

CMO
carlo.russo@genenta.com
+1 609 8181131

Asset type

Autologous Gene Therapy

Asset Development Phase

Phase I/II

Meeting's Goal

Fundraising / partnership

Clinical indication / Target market

Multiple Myeloma Newly Diagnosed Glioblastoma.

Asset Description

Temferon: A subpopulation of tumor-infiltrating monocytes engineered with exvivo lentiviral gene therapy and microRNA targeting to express interferon- α specifically in the tumor microenvironment.

NOTES



AREA OF ACTIVITY

Software as Medical Device, A.I.,
Bioinformatics, Big data analytics

FOUNDATION

07/03/17

COMPANY SIZE

Turnover

Less than 75.000 Euro

Employees

From 3 to 9 employees

INFO

HEADQUARTER

Via Nemorense, 91
Rome (RM)
Italy
www.genomeup.com

KEY CONTACT

Giovanni Stracquadaneo

CEO
giovanni@genomeup.com
+39 339 8448838
+1 510 5707705

Simone Gardini

CSO
simone@genomeup.com
+39 392 2622788

Asset type

Software as medical device

Asset Development Phase

Prototype, pre- certification (CE IVD)

Meeting's Goal

Fundraising (Seed Stage)

Clinical indication / Target market

Rare genetic diseases.

Asset Description

Clinical Decision Support cloud platform to diagnose and treat rare genetic diseases analyzing patient's whole exome or whole genome.

NOTES



AREA OF ACTIVITY

Manufacturing & process engineering

FOUNDATION

15/04/16

COMPANY SIZE

Turnover

Less than 75.000 Euro

Employees

From 10 to 19 employees

INFO

HEADQUARTER

1760 Cesar Chaves Street,
Unit D, San Francisco, CA, 94124
USA
www.multiplylabs.com

KEY CONTACT

Federico Parietti

Co-Founder and CEO
fred@multiplylabs.com
+1 6175832315

Asset type

Robotic, fully automated manufacturing system that produces personalized therapies on-demand.

Asset Development Phase

Since our first product is a personalized combination of three generic cardiovascular drugs, we only need a bioequivalence study to bring it to the market (we already submitted a pre-IND to the FDA). We are also working with pharmaceutical companies, and in that case we manufacture for them personalized products for Phase 1 and Phase 2 clinical trials.

Meeting's Goal

Fundraising (Series A). Partnerships for drug co-development (e. g. new personalized combinations of multiple drugs). Partnerships for distribution of our technology in Italy/ Europe.

Clinical indication / Target market

Robotic technology that enables the production of personalized therapies. Applications include all indications that require the combination of multiple drugs and their personalized dosing. We are starting, as a case study, from personalized combinations of cardiovascular drugs.

Asset Description

We developed a robotic production system that manufactures one personalized daily capsule for each patient. The capsule contains the whole prescription of that patient (a combination of drugs, each in the exact dosage).

NOTES

AREA OF ACTIVITY

Pharmaceutics

FOUNDATION

08/11/89

COMPANY SIZE

Turnover

From 250.000 to 750.000 Euro

Employees

More than 499 employees

INFO

HEADQUARTER

Via Artemisia Gentileschi, 26
Naples (NA)
Italy
www.petrone.it

KEY CONTACT

Pierluigi Petrone

CEO
pierluigi@petrone.it
+39 335 493932

Barbara Carrano

Executive assistant
b.carrano@petrone.it
+39 081 2415260

Asset type

Service Company offering international Pharma and Biotech companies expanding into Europe.

Asset Development Phase

NA

Meeting's Goal

Partnerships, M&A, equity investments.

Clinical indication / Target market

Clinical trials supplies through the newly established US branch (NY)

Asset Description

Point of Access platform to the European Market.

NOTES

AREA OF ACTIVITY

Biotech

FOUNDATION

01/04/14

COMPANY SIZE

Turnover

Less than 75.000 Euro

Employees

From 50 to 99 employees

INFO

HEADQUARTER

Via Valosa di Sopra, 9

Monza (MB)

Italy

www.rottapharmbiotech.com

KEY CONTACT

Lucio Rovati

Chief Executive Officer

lucio.rovati@rottapharmbiotech.com

+39 039 9066104

Federica Girolami

Director Business Development, Scientific

Liaison and Drug Safety

federica.girolami@rottapharmbiotech.com

+39 039 9066089

Asset type

Small Molecule

Asset Development Phase

Ready for a Phase II trial in combination with ICIs in patients with advanced cancer and/ or inadequate response to ICIs.

Meeting's Goal

Out-licensing Financing.

Clinical indication / Target market

Cancer: Immuno-oncology.

Asset Description

Immunotherapy has dramatically changed oncology therapy from palliative care to curative treatment. However, immunotherapy does not work for ~50% of patients with responsive cancers, and many solid tumors are not responsive at all. Recent studies have demonstrated that combination therapies of immune checkpoint inhibitors (ICIs) and other immunomodulators can improve the patient's response. Prostaglandin EP4 signaling plays a major immunosuppressive role in the tumor microenvironment, favoring tumor progression. Experimental evidence suggests that the immunomodulator CR6086 may improve the response of tumors to ICIs.

NOTES

AREA OF ACTIVITY

Diagnostic IVD

FOUNDATION

05/05/04

COMPANY SIZE

Turnover

From 250.000 to 750.000 Euro

Employees

From 20 to 49 employees

INFO

HEADQUARTER

Via Francesco Olgiati, 5
Milan (MI)
Italy
www.tethis-lab.com

KEY CONTACT

Marco Dario Rissoglio

General Manager
marco.rissoglio@tethis-lab.com
+39 02 36568349

Asset type

Diagnostics

Asset Development Phase

Pilot Clinical Studies.

Meeting's Goal

Fund Raising.

Clinical indication / Target market

Liquid biopsy/early cancer detection B71.

Asset Description

A proprietary functionalized slide and pre-analytical automatic system as the core technology of a diagnostic platform with high sensitivity in detecting cancer at its earliest stages from a blood sample.

NOTES



WISE S.R.L.

AREA OF ACTIVITY

Medical devices

FOUNDATION

09/02/11

COMPANY SIZE

Turnover

Less than 75.000 Euro

Employees

From 10 to 19 employees

INFO

HEADQUARTER

Via Michelangelo Buonarroti, 38
Cologno Monzese (MI)
Italy
www.wiseneuro.com

KEY CONTACT

Luca Ravagnan

CEO
luca.ravagnan@wiseneuro.com
+39 333 7657189

Giulia Salzano

CFO
giulia.salzano@wiseneuro.com
+39 349 0093234

Asset type

Medical Devices

Asset Development Phase

Clinical Phase

Meeting's Goal

Fundraising / M&A

Clinical indication / Target market

Neuroelectrodes for Intraoperative Neuromonitoring (during brain tumor resection) & for Spinal Cord Stimulation (for chronic pain treatment)/Neuromonitoring Market & Neuromodulation Market.

Asset Description

Highly compliant and minimally invasive neuroelectrodes.

NOTES



NOTES



NOTES

A series of horizontal lines provided for writing notes, consisting of 19 evenly spaced lines.





ITALIAN TRADE AGENCY

LOS ANGELES

1900 Avenue of the Stars
Suite 350
Los Angeles, CA 90067
T. +1 323 879 0950
F. +1 310 203 8335
losangeles@ice.it

CHICAGO

401 N. Michigan Avenue
Suite 1720
Chicago, IL 60611
T. +1 312 670 4360
F. +1 312 670 5147
chicago@ice.it

HOUSTON

777 Post Oak Blvd
Suite 320
Houston, TX 77056
T. +1 281 888 4288
F. +1 281 974 3100
houston@ice.it

MIAMI

1 SE 3rd Avenue
Suite 1000
Miami, FL 33131
T. +1 305 461 3896
F. +1 786 497 8900
miami@ice.it

NEW YORK

33 East 67th Street
New York, NY 10065
T. +1 212 980 1500
F. +1 212 758 1050
newyork@ice.it

ROME

Via Liszt, 21
00144 Rome, Italy
T. +39 06 59921
F. +39 06 89280353
fdi@ice.it

ITA network
www.ice.it

